What Biogen's 8-K filings say: 8 filings, latest Jul 1, 2026

Biogen filed its latest 8-K with the SEC on Jul 1, 2026. It discusses acquisition announced, capex increase and margin pressure.

Public (BIIB)Biotechnology Research10,000+ employeesbiogen.comLinkedIn

Filed: Jul 1, 2026
Filings: 8
Signals: 25

8-K · latest 10

What Biogen's 8-K filings say

8-K
Filed Jul 1, 2026 · 3 signals
SEC EDGAR
- Acquisition announcedPositive
  Biogen to spend up to $484M on R&D acquisitions and licensing deals in Q2 & Q3 2026
  Biogen is allocating significant capital for external innovation, with up to $484 million earmarked for acquiring R&D assets and funding collaboration agreements.
  $484M
  Maximum expected expense for acquired in-process research and development, upfront payments, and milestones across Q2 and Q3 2026 ($164M in Q2 + up to $320M...
- Margin pressureNegative
  Biogen flags up to $484M in R&D charges, pressuring Q2 & Q3 earnings.
  Biogen is absorbing a $164M charge in Q2 and forecasts another $290M-$320M in Q3 for R&D deals, significantly impacting profitability.
  $484M
  Total expected R&D-related charges against earnings for Q2 and Q3 2026 (using $164M for Q2 and high-end $320M for Q3).
- Capex increasePositive
  Biogen investing over $450M in external R&D acquisitions and partnerships.
  Biogen is executing a major capital allocation strategy, spending $164M in Q2 and up to $320M more in Q3 to acquire R&D assets and fund collaborations.
  $484M
  Total investment in external R&D, including acquisitions and collaborations, across Q2 and Q3 2026 (using $164M for Q2 and high-end $320M for Q3).
8-K
Filed Jun 10, 2026 · 2 signals
SEC EDGAR
- RestructuringNeutral
  Biogen completes acquisition of Apellis Pharmaceuticals, triggering post-merger integration and restructuring.
  The consummation of the merger with Apellis Pharmaceuticals will require significant organizational restructuring to integrate operations, personnel, and technology platforms.
- Acquisition completedNeutral
  Biogen completes acquisition of Apellis Pharmaceuticals, disclosed on May 14, 2026.
  The integration of Apellis Pharmaceuticals will require Biogen to consolidate systems, processes, and personnel across finance, IT, HR, and R&D.
8-K
Filed May 14, 2026 · 5 signals
SEC EDGAR
- Acquisition completedNeutral
  Biogen completes $5.3B acquisition of Apellis Pharmaceuticals, funded by $2B in new debt.
  Biogen has completed its acquisition of Apellis, triggering a massive post-merger integration effort.
  $5.3B
  Aggregate amount paid for the acquisition of Apellis Pharmaceuticals
  Apellis Pharmaceuticals, Inc.
- Restructuring chargeNeutral
  Biogen completes $5.3B acquisition of Apellis, initiating major post-merger integration.
  The acquisition of Apellis for approximately $5.3 billion necessitates a massive integration of all business functions, including IT systems, supply chains, R&D, and sales operations.
  $5.3B
  Aggregate payment for the acquisition of Apellis Pharmaceuticals
  Equiniti Trust Company, LLC
- Material contractNeutral
  Biogen secures $2B term loan from U.S. Bank to finance Apellis acquisition.
  Biogen has taken on $2 billion in new debt, increasing financial scrutiny and the need for robust financial planning, reporting, and treasury management systems.
  $2B
  New unsecured term loan facilities to finance acquisition
  U.S. Bank National AssociationS&P Global RatingsMoody’sBank of America, N.A.
8-K
Filed Apr 6, 2026 · 3 signals
SEC EDGAR
- Material contractPositive
  Biogen to incur $34M in Q1 expenses for R&D collaborations and asset acquisitions.
  $34M
  Acquired in-process research and development, upfront and milestone expense
- Margin pressureNegative
  Biogen expects a $0.19 per share negative impact to Q1 2026 earnings due to a $34M charge.
  A $34 million charge for R&D and collaboration expenses is expected to reduce Biogen's Q1 2026 net income per share by approximately $0.19.
  $34M
  Pre-tax charge causing impact to net income per diluted share

Earlier 8-K filings

8-KFiled Mar 31, 2026 · 5 signalsSEC EDGAR
8-KFiled Mar 11, 2026 · 3 signalsSEC EDGAR
8-KFiled Feb 11, 2026 · 3 signalsSEC EDGAR
8-KFiled Jan 13, 2026 · 1 signalSEC EDGAR

Showing 10 of 25 filing signals. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Biogen with the Signal API

One POST /v1/companies/enrich call with biogen.com returns Biogen 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","signal_types":["sec-8k"],"limit":20}'

Same industry

Questions about Biogen 8-K

When did Biogen file its latest 8-K?

Biogen filed its latest 8-K on Jul 1, 2026. The one before it was filed on Jun 10, 2026.

What did Biogen disclose in its latest 8-K?

From the filing dated Jul 1, 2026: Biogen to spend up to $484M on R&D acquisitions and licensing deals in Q2 & Q3 2026

Where can I read Biogen's 8-K filing?

The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/875045/000087504526000068/biib-20260701.htm. This page summarizes what the filing says and links to it.

Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of Sep 30, 2026.

How this data is built →Get it from the Signal API →

What Biogen's 8-K filings say: 8 filings, latest Jul 1, 2026

What Biogen's 8-K filings say

Track Biogen with the Signal API

8-K at related companies

Questions about Biogen 8-K